Lappaol F, an anticancer agent, inhibits YAP via transcriptional and post-translational regulation

Pharm Biol. 2021 Dec;59(1):619-628. doi: 10.1080/13880209.2021.1923759.

Abstract

Context: Lappaol F (LAF), a natural lignan from Arctium lappa Linné (Asteraceae), inhibits tumour cell growth by inducing cell cycle arrest. However, its underlying anticancer mechanism remains unclear.

Objective: The effects of LAF on the Hippo-Yes-associated protein (YAP) signalling pathway, which plays an important role in cancer progression, were explored in this study.

Materials and methods: Cervical (HeLa), colorectal (SW480), breast (MDA-MB-231) and prostate (PC3) cancer cell lines were treated with LAF at different concentrations and different durations. BALB/c nude mice bearing colon xenografts were intravenously injected with vehicle, LAF (10 or 20 mg/kg) or paclitaxel (10 mg/kg) for 15 days. The expression and nuclear localisation of YAP were analysed using transcriptome sequencing, quantitative PCR, western blotting and immunofluorescence.

Results: LAF suppressed the proliferation of HeLa, MDA-MB-231, SW480 and PC3 cells (IC50 values of 41.5, 26.0, 45.3 and 42.9 μmol/L, respectively, at 72 h), and this was accompanied by significant downregulation in the expression of YAP and its downstream target genes at both the mRNA and protein levels. The expression of 14-3-3σ, a protein that causes YAP cytoplasmic retention and degradation, was remarkably increased, resulting in a decrease in YAP nuclear localisation. Knockdown of 14-3-3σ with small interfering RNA partially blocked LAF-induced YAP inhibition and anti-proliferation effects. In colon xenografts, treatment with LAF led to reduced YAP expression, increased tumour cell apoptosis and tumour growth inhibition.

Conclusion: LAF was shown to be an inhibitor of YAP. It exerts anticancer activity by inhibiting YAP at the transcriptional and post-translational levels.

Keywords: 14-3-3σ; Yes-associated protein; apoptosis; cell proliferation; colon xenografts; tumour suppression.

MeSH terms

  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / pharmacology
  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Benzofurans / pharmacology*
  • Cell Cycle Proteins / antagonists & inhibitors*
  • Cell Cycle Proteins / biosynthesis
  • Cell Cycle Proteins / genetics*
  • Dose-Response Relationship, Drug
  • Female
  • HeLa Cells
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Protein Processing, Post-Translational / drug effects*
  • Protein Processing, Post-Translational / physiology
  • Transcription Factors / antagonists & inhibitors*
  • Transcription Factors / biosynthesis
  • Transcription Factors / genetics*
  • Transcription, Genetic / drug effects*
  • Transcription, Genetic / physiology
  • Xenograft Model Antitumor Assays / methods

Substances

  • Antineoplastic Agents, Phytogenic
  • Benzofurans
  • Cell Cycle Proteins
  • Transcription Factors
  • YY1AP1 protein, human
  • lappaol F
  • 4-Butyrolactone

Grants and funding

This work was supported by Project of Science and Technology of Guangdong [grant number 2016A020217015] and Guangzhou University of Chinese Medicine [grant number 2016KYTD04 and A3-415008].